{"cdcTestId":"2020-0020","testcaseName":"2nd dose of Covid-19 Vaccine different product (Pfizer) at 28 days ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-01-31T00:00:00","patient":{"dob":"1957-06-24T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-01-03T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-01-31T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-07-01T00:00:00","recommendedDate":"2022-07-01T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-01-03T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-01-31T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:37:37.887","generalDescription":"This test case describes when a patient is administered a different second dose of the Covid-19 vaccine at an interval of 28 days after the first dose, that the dose is valid, and a booster dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that individuals should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of a primary series (01/06/2022)\nv4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series."}